Mainstream

DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis

DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis

Post ContentdrrxRead More

You might also be interested in reading Prop Firm Funded7 Taps XM to Integrate Broker-Level Infrastructure.

March 27, 2025
In Mainstream